huMYBPC3 Mouse
Product Name
huMYBPC3 Mouse
Product ID
C001987
Strain Name
C57BL/6JCya-Mybpc3tm1(hMYBPC3)/Cya
Backgroud
C57BL/6JCya
Status
When using this mouse strain in a publication, please cite “huMYBPC3 Mouse (Catalog C001987) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
MYBPC3
Gene Alias
FHC, CMH4, CMD1MM, LVNC10, MYBP-C, cMyBP-C
NCBI ID
Chromosome
Chr 11 (Human)
MGI ID
Datasheet
Strain Description
MYBPC3 (myosin-binding protein C3) is a cardiac sarcomere-associated protein encoded by the MYBPC3 gene and serves as a key structural and functional regulator of cardiac contraction [1]. In normal tissues, MYBPC3 is predominantly expressed in the heart, where it plays critical roles in cardiac muscle contraction, sarcomere assembly, and heart rate regulation. Dysfunction of this protein is closely associated with various cardiomyopathies. Mutations in MYBPC3 represent one of the most common genetic causes of familial hypertrophic cardiomyopathy (HCM), with the majority being truncating mutations that lead to haploinsufficiency. These mutations can result in cardiac hypertrophy, fibrosis, arrhythmias, heart failure, and an increased risk of sudden cardiac death [2-3]. In addition, MYBPC3 variants are also associated with dilated cardiomyopathy (DCM) and other forms of cardiomyopathy [4].
The huMYBPC3 mouse is a humanized model generated by replacing the sequence from the start codon to the 3'UTR in the murine Mybpc3 gene with the corresponding sequence of human MYBPC3. This model is suitable for evaluating the in vivo efficacy and safety of MYBPC3-targeted therapeutics, including gene therapies (such as AAV-mediated delivery), small-molecule drugs, and gene editing therapies. Furthermore, it is applicable to research on the pathogenesis of hypertrophic cardiomyopathy (HCM) and other MYBPC3-related cardiomyopathies, as well as studies on cardiac function, sarcomere structure, and combination therapy strategies.
Reference
Zou X, Ouyang H, Lin F, Zhang H, Yang Y, Pang D, Han R, Tang X. MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis. Cell Death Dis. 2022 Nov 10;13(11):948.
Greer-Short A, Greenwood A, Leon EC, Qureshi TN, von Kraut K, Wong J, Tsui JH, Reid CA, Cheng Z, Easter E, Yang J, Ho J, Steltzer S, Budan A, Cho M, Chandrakumar R, Cisne-Thompson O, Feathers C, Chung TW, Rodriguez N, Jones S, Alleyne-Levy C, Liu J, Jing F, Prince WS, Lin J, Ivey KN, Tingley WG, Hoey T, Lombardi LM. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat Commun. 2025 Mar 4;16(1):2196.
Tudurachi BS, Zăvoi A, Leonte A, Țăpoi L, Ureche C, Bîrgoan SG, Chiuariu T, Anghel L, Radu R, Sascău RA, Stătescu C. An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy. Int J Mol Sci. 2023 Jun 22;24(13):10510.
Lu Y, Wang Z, Zhang S, Liu Y, Jin Y, Tian Z, Zhang S. Genetic landscape of hereditary cardiomyopathies and arrhythmias in China. J Genet Genomics. 2025 Jul 11:S1673-8527(25)00200-0.
Strain Strategy
The sequences from the start codon to the 3'UTR of the endogenous mouse Mybpc3 gene were replaced with the sequences from the start codon to the 3'UTR of the human MYBPC3 gene.
Figure 1. Gene editing strategy for huMYBPC3 mice.
Application Area
Development and screening of MYBPC3-targeted therapies;
Investigation of pathogenic mechanisms and therapeutic strategies for MYBPC3-related cardiomyopathies, including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM);
In vivo efficacy evaluation of sarcomere modulators, calcium sensitizer antagonists, and other small molecules or biologics for improving cardiac function;
Monitoring plasma MYBPC3 fragments, NT-proBNP, and other biomarkers to establish systems for disease progression and therapeutic efficacy assessment;
Assessment of systemic toxicity and immunogenicity of long-term cardiac-targeted administration and gene editing strategies.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
